

## Juxtapid - (EQ 5MG BASE,EQ 10MG BASE,EQ 20MG BASE,EQ 30MG BASE,EQ 40MG BASE,EQ 60MG BASE ; Capsule)

<b>Generic Name</b>	Lomitapide	<b>Innovator</b>	Chiesi U.S.A
<b>Dosage</b>	EQ 5MG BASE,EQ 10MG BASE,EQ 20MG BASE,EQ 30MG BASE,EQ 40MG BASE,EQ 60MG BASE ; Capsule	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	None	<b>Known Para IV Filers</b>	None
<b>Other ANDA developers</b>	None	<b>Tentative Approvals</b>	None
<b>Final Approvals</b>	None	<b>Generic Launches</b>	None
<b>Indication</b>	JUXTAPID is a microsomal triglyceride transfer protein inhibitor indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-highdensity lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events



Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.